Companies × risks
Novartis
Novartis deploys AI across R&D and operations through a strategic partnership with Microsoft (founding the Novartis AI innovation lab) and broad enterprise AI enablement. It also develops specialised AI models and applications for drug discovery and life sciences through its AI innovation lab.
We reviewed 6 public documents from Novartis and found it acknowledges 6 of 24 AI risks, including discrimination and loss of privacy.
Sector: Agriculture, Mining, Construction and Manufacturing; Chemicals & pharmaceutical manufacturing
Roles: AI deployer; Specialized AI developer
AI risks Novartis acknowledges
- Discrimination: “Ensure AI training Data is representative and free from bias that could lead to discrimination against certain groups or individuals.” (Ethical Use of Data and Technology Policy)
- Loss of privacy: “If we do not have sufficient rights to use the data... we may also incur liability through the violation of... privacy... rights” (Novartis Annual Report 2025 - Form 20-F)
- False information: “AI systems are susceptible to producing false or "hallucinatory" inferences or outputs” (Novartis Annual Report 2025 - Form 20-F)
- Capability & robustness: “AI algorithms may be flawed, insufficient, of poor quality... or contain other errors or inadequacies - any of which may not be easily detectable. AI systems are susceptible to producing false or "hallucinatory" inferences or outputs” (Novartis Annual Report 2025 - Form 20-F)
- Devaluation of human creativity: “If we do not have sufficient rights to use the data or other material or content on which our AI solutions or other AI tools we use rely, we may also incur liability through the violation of applicable laws and regulations, third-party intellectual property, privacy or other rights, or contracts to which we are a party.” (Novartis Annual Report 2025 - Form 20-F)
- Transparency & interpretability: “ensuring transparency... addresses key risk areas such as transparency, explainability” (Our commitment to ethical and responsible use of Artificial ...)
Documents we reviewed
- Ethical Use of Data and Technology Policy (Corporate policy, 2025)
- Novartis Q1 2026 Impact and Sustainability Update (Investor materials, 2026)
- Appendix 6 to Novartis BCR (Corporate policy, 2024)
- Novartis - Our commitment to ethical and responsible use of Artificial Intelligence (AI overview & principles, 2025)
- Our commitment to ethical and responsible use of Artificial ... (AI overview & principles, 2025)
- Novartis Annual Report 2025 - Form 20-F (Annual report, 2026)